Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”

Science Signaling  04 Dec 2012:

DOI: 10.1126/scisignal.2003734


Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) play important roles in tumor growth, which has stimulated efforts toward the design of targeted cancer therapeutics that inhibit their function. A growing body of literature indicates that EGFR and mTOR are also essential to support a functional innate immune response. Hence, although combination therapies that block both EGFR and mTOR may have improved activity against tumors, they may also place patients at risk of fulminant infections. We discuss data supporting this hypothesis.

Full text available 11 December 2012, Vol. 5, Issue 254, lc5